Jak Inhibitors: A New Weapon in the Skin Care Providers' Arsenal

    March 2023 in “ PubMed ”
    Osaigbokan Aihie, John A. Dyer
    Studysummary This review discusses JAK inhibitors as promising new treatments for various chronic dermatologic conditions, including some recent drug approvals, and reports no new clinical results.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on pmc.ncbi.nlm.nih.gov →
    Discuss this study in the Community →

    Research cited in this study 4

    1. JAK Inhibitors in Dermatology: The Promise of a New Drug Class Journal of the American Academy of Dermatology · 2017
    2. Oral Ruxolitinib Induces Hair Regrowth in Patients with Moderate-to-Severe Alopecia Areata JCI insight · 2016
    3. Familial Aggregation of Alopecia Areata Journal of the American Academy of Dermatology · 2016
    4. Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis Journal of Investigative Dermatology · 2014

    Related research 2

    1. Jak Inhibitors: A New Weapon in the Skin Care Providers' Arsenal PubMed · 2023
    2. Oral Tofacitinib: A Promising Treatment in Atopic Dermatitis, Alopecia Areata, and Vitiligo Clinical and Experimental Dermatology · 2017